BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25326835)

  • 1. [Not Available].
    Salvador J; Gaztambide S
    Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 3. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lixisenatide for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):19-21. PubMed ID: 28118649
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-acting preparations of exenatide.
    Cai Y; Wei L; Ma L; Huang X; Tao A; Liu Z; Yuan W
    Drug Des Devel Ther; 2013; 7():963-70. PubMed ID: 24039406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 9. New Injectable Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Diamant M; Kramer MH; Cahen DL; van Raalte DH
    Diabet Med; 2017 Apr; 34(4):591-592. PubMed ID: 27278095
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly glucagon-like peptide 1 receptor agonists.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
    Syed YY; McCormack PL
    Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 16. [Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
    MMW Fortschr Med; 2005 Aug; 147(31-32):54-5. PubMed ID: 16128202
    [No Abstract]   [Full Text] [Related]  

  • 17. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Tsutsumi Y; Tsujimoto Y; Ikenoue T
    N Engl J Med; 2016 Mar; 374(11):1094-5. PubMed ID: 26981946
    [No Abstract]   [Full Text] [Related]  

  • 18. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Probstfield JL
    N Engl J Med; 2016 Mar; 374(11):1095-6. PubMed ID: 26981945
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes: Lixisenatide does not increase rates of CVD events.
    Huynh K
    Nat Rev Cardiol; 2016 Feb; 13(2):63. PubMed ID: 26701217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.